BELFOR
22.6.2022 17:39:12 CEST | Business Wire | Pressemeddelelse
BELFOR, verdens største skadeservicevirksomhed og SSG, førende på det skandinaviske marked inden for skadesanering og genopbygning, har slået sig sammen for at styrke vores kundeservice i Danmark, Norge og Sverige.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220622005634/da/
BELFOR har nu mere end 12.500 medarbejdere og 500+ lokationer i hele verden. Vi dækker alle led, når det kommer til genopbygning efter en skade. Vi vurderer skaden, igangsætter nødvendige foranstaltninger, og vi sørger for renovering og genopbygning, uanset skadens omfang.
SSG Group tilbyder bl.a. skadeservice, renovering og genopbygning og har 980 medarbejdere, fordelt på 57 lokationer i Danmark, Sverige og Norge.
"Med SSG udvider vi vores dygtige og erfarne teams med gode folk, øger vores servicekapacitet og optimerer vores responstider for vores nationale og internationale kunder", udtaler Elvir Kolak, CEO for BELFOR Europe.
"Denne transaktion betyder et enormt løft for vores organisationer i Danmark, Norge og Sverige. Ved at kombinere BELFORS tekniske kompetencer med vores serviceportefølje åbner vi for nye udviklingsmuligheder for vores medarbejdere", tilføjer Carsten Fensholt, CEO for SSG Group.
"Vi er glade for at byde SSG velkommen i BELFOR-familien, og vi glæder os til at medvirke til deres fremtidige vækst. SSG beskæftiger fantastiske medarbejdere og har stort fokus på kunderne – og er derfor et perfekt match for os! Vi er stolte over at få dem ombord. Hos BELFOR er vores vækstplaner ambitiøse, og vi leder aktivt efter gode virksomheder, der kan tilslutte sig BELFOR-familien – både i Skandinavien og resten af Europa", afslutter Sheldon Yellen, global CEO hos BELFOR.
Fremover vil BELFOR være Danmarks førende skadeservicevirksomhed med tilføjelsen af 650 nye medarbejdere. Opkøbet af SSG er et stort skridt på vejen mod en større tilstedeværelse i Skandinavien, som startede med erhvervelsen af det danske skadeservicefirma, Røsva, efterfulgt af Rølund i 2021.
OM BELFOR
BELFOR er førende på det globale marked inden for skadeservice. Med mere end 40 års erfaring kan vi hos BELFOR tilbyde at hjælpe dig igennem hele dit skadesforløb, lige fra vurdering af skaden, til renovering og genopbygning. Det betyder bl.a., at vi er den foretrukne partner både for forsikringsselskaber samt kommercielle og private kunder. Med SSG under fanen har BELFOR nu mere end 12.500 ansatte og 500 lokationer i 57 lande. Vi er klar til at hjælpe vores kunder 24 timer i døgnet, 365 dage om året, uanset hvor store og komplekse skaderne er.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220622005634/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum